Zacks: Brokerages Anticipate Prevail Therapeutics Inc. (NASDAQ:PRVL) Will Post Earnings of -$0.50 Per Share

Equities research analysts predict that Prevail Therapeutics Inc. (NASDAQ:PRVL) will report ($0.50) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Prevail Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.55) and the highest estimate coming in at ($0.48). The business is expected to issue its next earnings results on Wednesday, November 13th.

On average, analysts expect that Prevail Therapeutics will report full year earnings of ($2.53) per share for the current financial year, with EPS estimates ranging from ($3.30) to ($2.07). For the next financial year, analysts anticipate that the company will post earnings of ($2.11) per share, with EPS estimates ranging from ($2.48) to ($1.91). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover Prevail Therapeutics.

Prevail Therapeutics (NASDAQ:PRVL) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.58) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.24) by $0.66.

Several research firms have recently issued reports on PRVL. Morgan Stanley began coverage on Prevail Therapeutics in a research note on Monday, July 15th. They issued an “overweight” rating and a $20.00 price target for the company. Cowen began coverage on Prevail Therapeutics in a research note on Monday, July 15th. They issued an “outperform” rating for the company. Bank of America began coverage on Prevail Therapeutics in a research note on Monday, July 15th. They issued a “buy” rating and a $15.00 price target for the company. Zacks Investment Research raised Prevail Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research note on Thursday, October 17th. Finally, Wedbush reissued a “buy” rating and issued a $20.00 price target on shares of Prevail Therapeutics in a research note on Friday, November 1st. Five equities research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average target price of $16.50.

Large investors have recently added to or reduced their stakes in the company. Blackstone Group Inc bought a new position in shares of Prevail Therapeutics in the second quarter worth $66,000. Point72 Hong Kong Ltd bought a new position in Prevail Therapeutics during the second quarter valued at about $106,000. Morgan Stanley bought a new position in Prevail Therapeutics during the second quarter valued at about $166,000. Northern Trust Corp bought a new position in Prevail Therapeutics during the second quarter valued at about $188,000. Finally, SG Americas Securities LLC bought a new position in Prevail Therapeutics during the second quarter valued at about $194,000. 77.49% of the stock is owned by institutional investors.

NASDAQ PRVL traded up $1.12 on Friday, reaching $12.30. The company had a trading volume of 95,300 shares, compared to its average volume of 107,080. Prevail Therapeutics has a 1 year low of $7.41 and a 1 year high of $16.90. The firm’s 50-day moving average is $11.27. The company has a quick ratio of 26.94, a current ratio of 26.94 and a debt-to-equity ratio of 0.04.

About Prevail Therapeutics

Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.

Recommended Story: What is a Lock-Up Period?

Get a free copy of the Zacks research report on Prevail Therapeutics (PRVL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Prevail Therapeutics (NASDAQ:PRVL)

Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.